title: Is there a role for cannabidiol in psychiatry?
abstract: Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic disorders, anxiety disorders, depression, bipolar disorder and substance-use disorders.
  
  
  
  We conducted a literature search in PubMed, Scielo, and Clinicaltrials.gov databases. Evidence was classified according to the WFSBP task forces standards.
  
  
  
  Bibliographic research yielded 692 records. After analysis, we included six case reports and seven trials, comprising 201 subjects. Most the studies published presented several drawbacks and did not reach statistical significance. We have not found evidence regarding major depressive and bipolar disorders. The level of evidence for cannabis withdrawal is B; cannabis addiction is C2; treatment of positive symptoms in schizophrenia and anxiety in social anxiety disorder is C1. Discrete or no AEs were reported. The most frequently reported AEs are sedation and dizziness.
  
  
  
  The evidence regarding efficacy and safety of CBD in psychiatry is still scarce. Further larger well-designed randomised controlled trials are required to assess the effects of CBD in psychiatric disorders.
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.|b Postgraduation Program in Molecular Medicine , School of Medicine, Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Julia Machado
authors.identifier: 0000-0001-8842-4972
authors.initials: JM
authors.lastname: Khoury
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Maila de Castro Lourenço das
authors.identifier: 0000-0003-4125-3736
authors.initials: MCLD
authors.lastname: Neves
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Marco Antônio Valente
authors.identifier: 0000-0003-2282-5647
authors.initials: MAV
authors.lastname: Roque
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Daniela Alves de Brito
authors.identifier: 0000-0003-3671-397X
authors.initials: DAB
authors.lastname: Queiroz
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: André Augusto
authors.identifier: 0000-0001-9907-3645
authors.initials: AA
authors.lastname: Corrêa de Freitas
authors.affiliation: c Department of Chemistry , Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Ângelo
authors.identifier: 0000-0003-2344-5590
authors.initials: Â
authors.lastname: de Fátima
authors.affiliation: d Department of Pharmacology, Institute of Biological Sciences , Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.
authors.forename: Fabrício A
authors.identifier: 0000-0002-0824-7302
authors.initials: FA
authors.lastname: Moreira
authors.affiliation: a Department of Mental Health , Federal University of Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.|b Postgraduation Program in Molecular Medicine , School of Medicine, Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.|e INCT de Medicina Molecular, Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , MG , Brazil.|f Unité Inserm U1073 , Rouen , France.
authors.forename: Frederico Duarte
authors.identifier: 0000-0003-1926-9053
authors.initials: FD
authors.lastname: Garcia
mesh_terms: D002185:Cannabidiol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*
chemical_list: D002185:Cannabidiol
keywords: Cannabidiol; adverse effects; pharmacotherapy; psychiatric disorders; psychiatry